首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献，搜索用时 421 毫秒
1.
本试验研究单剂量口服喹赛多(200 mg/kg体重)后,其主要代谢物脱二氧喹赛多(1.4-bisdesoxycyadox)在健康大鼠血浆及各组织内的药代动力学特征。灌服后在设定的时间点用剖杀的方法采集血浆及组织,经处理后,利用液相色谱-串联质谱法测定血浆及各组织中的药物浓度。通过Win Nonlin 6.1软件,用非房室模型统计矩原理计算脱二氧喹赛多在血浆及各组织中的药动学参数。主要药动学参数分别为血浆:T1/2β(4.63)h,Cmax(1534.00)μg/L,AUC0→∞(9937.08)h*μg/L,MRT(8.49)h;肝脏:T1/2β(32.45)h,Cmax(1982.50)μg/L,AUC0→∞(15489.71)h*μg/L,MRT(10.04)h;肾脏:T1/2β(18.96)h,Cmax(1286.67)μg/L,AUC0→∞(7671.06)h*μg/L,MRT(9.08)h;肌肉:T1/2β(10.19)h,Cmax(2293.33)μg/L,AUC0→∞(16154.84)h*μg/L,MRT(9.00)h;脂肪:T1/2β(8.47)h,Cmax(711.50)μg/L,AUC0→∞(5107.22)h*μg/L,MRT(8.79)h。脱二氧喹赛多在大鼠血浆及各组织中的消除速率缓慢,达峰浓度高,分布较广泛。  相似文献   

2.
喹烯酮及其主要代谢物在猪体内的药动学研究   总被引：1，自引：1，他引：0  
本试验旨在研究喹烯酮及其主要代谢物在猪体内的药物代谢动力学过程。将喹烯酮按40 mg/kg的剂量对7头猪进行灌胃给药,采用HPLC-MS/MS法测定血浆中喹烯酮及其主要代谢物的浓度,药代动力学软件WinNonlin 5.2处理血浆中药物浓度－时间数据。灌胃给药后猪血浆中能检测到原药和N1-脱氧喹烯酮、脱二氧喹烯酮及3-甲基喹噁啉-2-羧酸(MQCA)3种代谢物。喹烯酮的浓度－时间数据符合一级吸收一室开放模型,其主要药代动力学参数为:T1/2Ka＝(0.97±0.08)h,T1/2λz＝(2.79±0.16)h,CL＝(26.03±0.65)L/h·kg,Cmax＝(0.26±0.01)μg/mL,Tmax＝(2.23±0.06)h,AUC＝(1.54±0.04)h·μg/mL;采用统计矩法处理N1-脱氧喹烯酮和脱二氧喹烯酮的浓度－时间数据,N1-脱氧喹烯酮主要药代动力学参数为:Tmax＝(6.33±1.37)h,Cmax＝(8.81±2.08) ng/mL,T1/2λz＝(3.03±1.27)h,AUC＝(0.07±0.01)h·ng/mL,MRT＝(6.58±0.40)h;脱二氧喹烯酮的主要药动学参数:Tmax＝(10.29±0.29)h,Cmax＝(6.20±1.11)ng/mL,T1/2λz＝(5.84±2.78)h,AUC＝(0.15±0.01)h·ng/mL,MRT＝(3.64±0.72)h。同时,在少数时间点检测到代谢物MQCA。猪口服喹烯酮后,吸收较快,消除较慢。血浆中检测到N1-脱氧喹烯酮、脱二氧喹烯酮及3-甲基喹噁啉-2-羧酸3种代谢物,且浓度较低、消除缓慢。  相似文献   

3.
为研究国产和进口硫酸头孢喹肟注射液(7.5%)在猪体内的药代动力学特征和生物等效性,采用双处理、双周期随机交叉试验设计,将20头健康三元杂交猪随机分成2组,按3mg/kg体重分别单剂量肌内注射受试制剂和参比制剂。采用超高效液相色谱-串联质谱法测定血浆中头孢喹肟的浓度,利用Win Nonlin6.3软件计算主要药动学参数,并评价两种制剂的生物等效性。结果显示,受试制剂和参比制剂的Tmax分别为2.30±0.73h和2.25±0.55h;Cmax分别为2.37±0.34μg/mL和2.45±0.36μg/mL;AUC0-t分别为26.38±2.30μg·h·mL^-1和24.86±2.19μg·h·mL^-1;AUC0-∞分别为26.74±2.34μg·h·mL^-1和25.07±2.20μg·h·mL^-1。硫酸头孢喹肟注射液受试制剂和参比制剂的AUC0-t、AUC0-∞、Cmax、Tmax均无显著性差异(P>0.05)。双单侧t检验结果显示两种制剂生物等效,临床上可相互替代。该试验可为兽医临床合理用药提供参考。  相似文献   

4.
通过喹赛多(Cyadox,CYX)在大鼠体内消除规律研究,了解其对食品安全的影响,并为今后的药理学和毒理学研究提供较为详细的数据基础,研究建立了喹赛多及其两种主要代谢产物脱二氧喹赛多(BDCYX)和喹噁啉-2-羧酸(QCA)的提取和HPLC检测方法,并以大鼠作为研究载体,按推荐剂量连续混饲给药7 d后,研究喹赛多及其两种代谢物在血浆、肌肉、肝脏中消除规律;一次性灌胃给药后研究喹赛多及其两种代谢物在排泄物中的消除规律特点。结果表明,CYX和BDCYX在0~24 h和24~48 h时间段的粪便中可大量检出,在血浆、肌肉、肝脏和尿液中未检出;QCA在6 h的肌肉中有少量残留,在肝脏中一直到72 h还有一定量的残留,在血浆和粪便中未发现其存在。本研究结果为今后喹赛多在体内处置研究提供了可直接借鉴的技术手段和理论基础。  相似文献   

5.
5种伊维菌素注射液在家兔体内的比较药动学研究   总被引：2，自引：1，他引：1  
试验旨在研究5种不同处方的伊维菌素注射液在家兔体内的比较药动学特征。50只健康家兔随机分为5组,通过单次给药剂量(5 mg/kg体重)皮下注射伊维菌素注射液,3P97药动学计算软件处理血浆药物浓度—时间数据。家兔皮下注射伊维菌素注射液属于一级吸收一室开放模型。自制伊维菌素注射液的:T1/2(Ka)(8.10±3.68) h、T1/2(Ke)(36.34±14.63) h、Tmax (22.38±8.63) h、 Cmax (354.01±57.75) ng/mL、 AUC (25843±3029) ng/(mL·h)。经SPSS统计学分析软件分析显示自制伊维菌素注射液的T1/2(Ka)、T1/2(Ke) 无显著性差异,但Cmax 分析显示与C、D存在显著性差异(P<0.05),与A、B无显著性差异(P>0.05),但明显高于A、B的Cmax。AUC平均值明显高于其余4种,说明自制伊维菌素注射液在家兔体内具有吸收好,消除快,生物利用度高等优点,临床可安全使用,具有更好的抗寄生虫作用。  相似文献   

6.
为检测猪、鸡可食性组织中喹噁啉类兽药残留标示物喹噁啉-2-羧酸(QCA)和3-甲基喹噁啉-2-羧酸(MQ-CA),建立了同时检测这2种残留标示物的高效液相色谱-串联质谱法.将样品碱水解,乙酸乙酯等液-液萃取,65℃氮气吹干,甲醇:0.5%甲酸水溶液(30:70)溶解,0.45μm微孔滤膜过滤后,采用高效液相色谱-串联质谱分析.结果显示,猪、鸡可食性组织中喹噁啉类兽药残留标示物MQCA和QCA检测限为0.2～0034μg/kg和0.5～0.9μg/kg,定量限为0.5～0.61μg/kg和0.77～1.31μg/kg.相对回收率在90.07%～106.8%范围内,日内变异系数≤13.69%.日间变异系数≤15.43%.MQCA和QCA在2～100μg/kg范围内具有较好的线性关系(r~2>0.99).结果表明,本方法简单、灵敏度高.适用于猪、鸡可食性组织中喹噁啉类兽药残留标示物的定量检测.  相似文献   

7.
头孢喹诺对临床分离菌株抗菌活性研究   总被引：1，自引：0，他引：1  
本研究旨在评价头孢喹诺对上海市养殖场临床分离菌株的体外抗菌作用,为头孢喹诺的临床使用提供参考依据。从上海市养殖场分离并鉴定大肠杆菌、沙门氏菌、金黄色葡萄球菌和链球菌各若干株,采用微量肉汤稀释法测定头孢喹诺对各菌株的最小抑菌浓度（MIC）、最小杀菌浓度（MBC）,推算MIC50和MIC90,并绘制头孢喹诺对这4种细菌的杀菌动力学曲线。头孢喹诺对金黄色葡萄球菌、链球菌、沙门氏菌和大肠杆菌的MIC50分别为0.063、0.063、0.032、0.125 μg/mL,MIC90分别为0.125、0.125、0.125、0.25 μg/mL;在很小的浓度变化范围内头孢喹诺能够快速抑菌,在抑菌浓度为1倍或2倍MIC时,24 h内能杀灭金黄色葡萄球菌、大肠杆菌或链球菌、沙门氏菌。头孢喹诺对上述几种临床分离细菌具有很强的抑菌效果和杀菌活性。  相似文献   

8.
癸氧喹酯溶液在鸡体内的药动学研究   总被引：2，自引：0，他引：2  
建立了鸡血浆中癸氧喹酯的高效液相-荧光检测法.结果表明,在0.02～10.0 μg/mL范围内,癸氧喹酯血药浓度呈线性关系.最低检测限为0.01μg/mL,回收率在84%以上,日内RSD小于6.87%.试验鸡按3 mg/kg体重分别经口单次灌服癸氧喹酯溶液剂和癸氧喹酯原料粉.给药后0.25～48 h内血药浓度均低于定量限(0.02μg/mL),无明显浓度变化曲线,无法进行药动学血药浓度-时间分析.  相似文献   

9.
《畜牧与兽医》2014,(7):73-76
为了解硫酸头孢喹肟口服和静注给药在鸡体内的动力学特征,用高效液相色谱法测定鸡血浆中的药物质量浓度,所得硫酸头孢喹肟血药浓度数据用3p97计算机软件处理。结果显示:硫酸头孢喹肟以每公斤体重10 mg单剂量静注给药,药物浓度-时间数据经药动学程序拟合符合无吸收二室开放动力学模型,主要药动学参数分别为:中央室分布容积V(c)(1.16±0.02)L·kg-1,分布半衰期T1/2α(0.29±0.03)h,消除半衰期T1/2β(1.69±0.24)h,曲线下面积AUC(6.57±0.18)mg·L-1·h,清除率CL/f(s)(1.53±0.04)mg·L-1·h。硫酸头孢喹肟以每公斤体重20 mg口服给药的血药浓度时间数据,符合一级吸收一室开放模型,主要动力学参数:吸收半衰期T1/2 ka(0.52±0.04)h,消除半衰期T1/2 ke(0.88±0.05)h,峰时Tmax(1.07±0.02)h,最高血药浓度Cmax(3.63±0.25)μg·mL-1,曲线下面积AUC(9.84±0.68)mg·L-1·h,表观分布容积V/f(c)(3.85±0.30)L·kg-1·h-1,生物利用度F(74.9±0.06)%。结果表明:硫酸头孢喹肟静注给药能迅速从血液分布进入组织中,在体液中具有良好的渗透和分布性能,体内分布广泛,能迅速从血液中消除。口服给药吸收迅速,达峰时间短。口服给药在鸡体内生物利用度稍低,可能由于硫酸头孢喹肟的脂溶性低,其在消化道吸收率低所致。但在8 h内能保持有效血药浓度范围(0.095.74μg·mL-1),可以有效控制常见细菌感染。  相似文献   

10.
文中进行了六氢β-酸月桂酸酯在鸡体内的药动学研究。将12只健康鸡随机分为2组,分别单剂量每千克体重40 mg/kg灌胃给药和1 mg/kg静注给药。在给药前后不同时间点从前腔静脉采集血样,分离血浆,用高效液相色谱法测定血浆中六氢β-酸月桂酸酯的浓度。用Winnon-lin5.2.1的非房室模型处理血浆药物浓度-时间数据。单剂量口服六氢β-酸月桂酸酯的主要药动学参数:Cmax(0.04±0.01)μg/ml,Tmax(1.00±0.15)h,T1/2(2.35±0.17)h,AUC(0.13±0.01)(h·μg)/ml,V(1 024.1±98.4)L/kg,CLB(302.2±7.6)L/(kg·h),MRT(3.55±0.27)h;单剂量静注六氢β-酸月桂酸酯的主要药动学参数:C0(1.25±0.17)μg/ml,T1/2(1.10±0.25)h,AUC(0.82±0.14)(h·μg)/ml,V(1.93±0.13)L/kg,CLB(1.25±0.21)L/(kg·h),MRT(1.27±0.31)h。结果表明:灌胃六氢β-酸月桂酸酯[40mg/(kg·bw)]与静脉注射六氢β-酸月桂酸酯[1 mg/(kg·bw)]相比,鸡灌胃给药的生物利用度为0.4%,灌胃给药后吸收极少,静注浓度较高,消除半衰期均较短。  相似文献   

11.
通过阿司匹林丁香酚酯(AEE)在大鼠体内代谢动力学的研究,探讨其在体内的代谢规律,为临床合理用药提供参考。选取12只SPF级SD大鼠,颈静脉插管后以20 mg/kg的剂量灌胃给药,采用LC-MS/MS法检测大鼠血浆中AEE及其代谢物的浓度,计算药动学参数。结果表明:AEE和代谢物阿司匹林在血浆中无法检出;代谢物丁香酚在血浆中浓度较低,未达到定量限;代谢物水杨酸血药浓度符合一室模型。水杨酸在大鼠体内的主要药代动力学参数C_(max)、T_(max)和CL分别为3356.90±1120.37 ng/mL、4.35±1.09 h、432.01±148.41 mL/h。该检测方法快捷、准确、灵敏度高,适用于大鼠血浆中AEE及其代谢物的血药浓度测定,为今后AEE在体内处置研究和给药间隔提供了技术参考和理论基础。  相似文献   

12.
The tissue kinetics of cyadox, an antibacterial agent used in food animals, and its major metabolites in pigs, chickens, and carp were investigated followed by a complete dietary exposure assessment to evaluate the food safety of cyadox. Cyadox and its major metabolites, bisdeoxycyadox (Cy1), 4‐desoxycyadox (Cy2), N ‐(quinoxaline‐2‐methyl)‐cyanide acetyl hydrazine (Cy4), quinoxaline‐2‐carboxylic acid (Cy6), and 2‐hydromethyl‐3‐hydroxy‐quinoxaline (Cy12), were simultaneously quantitated with a high‐performance liquid chromatography?ultraviolet (HPLC ‐UV ) method. Pigs, chickens, and carp were fed with 150 mg/kg cyadox in feed for consecutive 60, 40, and 30 days, respectively. The residue amount of cyadox and its major metabolites in liver, kidney, muscle, and fat (skin) tissues was determined. Cy2 was below the limit of quantitation even at the withdrawal time of 6 hr, cyadox, Cy4, Cy6, and Cy12 could be detected at 6–24 hr with low level less than 50 μg/kg. By contrast, Cy1 persisted for 3 days in the kidney of pigs and chickens, and in the liver of carp. Based on these residue depletion data and previous toxicology results, the global estimated chronic dietary exposure assessment of cyadox for general population was conducted, indicating a zero withdrawal time (WDT ) may be appropriate for cyadox in food animals when used in feed for prolonged administration. These results provide analytical techniques and safety standards suitable for residue monitoring of cyadox in food animals.  相似文献   

13.
The determination of the pharmacokinetic parameters of tramadol in plasma and a better characterization of its metabolites after oral administration to horses is necessary to design dosage regimens to achieve target plasma concentrations that are associated with analgesia. The purpose of this study was to determine the pharmacokinetics and elimination pattern in urine of tramadol and its metabolites after oral administration to horses. Tramadol was administered orally to six horses and its half-life, Tmax and Cmax in plasma were 10.1, 0.59 h, and 132.7 ng/mL, respectively. The half-life, Tmax and Cmax for M1 in plasma were 4.0, 0.59 h, and 28.0 ng/mL, respectively. Tramadol and its metabolites were detectable in urine between 1 and 24 h after the administration. In conclusion, the PK data reported in this study provides information for the design of future studies of tramadol in horses.  相似文献   

14.
采用超高效液相色谱串联四级杆/飞行时间质谱仪(UPLC-Q-TOF MS)识别和鉴定了喹赛多在鸡体内的代谢产物,并讨论了喹赛多在鸡体内可能的代谢途径。按800 mg/kg体重的剂量给鸡单次灌服喹赛多,采集试验前后鸡的粪便,经简单前处理后,运用UPLC-Q-TOF MS进行分析,采集的数据经Metabolynxxs软件处理后,共鉴定出15种喹赛多的代谢产物。试验结果表明,喹赛多在鸡体内发生广泛的代谢。  相似文献   

15.
As a newer anti-inflammatory agent, carbasalate calcium is used in various animal species. In this study, the pharmacokinetics of carbasalate calcium was investigated in broilers. Broilers, with body weight of 2.0 ± 0.3 kg, were administrated carbasalate calcium soluble powder at a single dose of 40 mg/kg body weight orally. The plasma concentrations of its metabolites, aspirin (ASA), salicylic acid (SA) and gentisic acid (GA) were determined by LC-MS/MS method and the pharmacokinetic parameters were calculated by noncompartmental analysis. After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively. The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively. In conclusion, analytical method for the quantification of ASA, SA and GA in plasma in the broilers was developed and validated. In broilers, carbasalate calcium is quickly metabolized in ASA and ASA is rapidly converted to SA and one of the metabolites of SA is GA.  相似文献   

16.
The pharmacokinetics of triclabendazole were evaluated in normal goats and in goats artificially infected with Fasciola hepatica. Triclabendazole and its metabolites were determined using a novel high performance liquid chromatographic method with fluorimetric detection after solid-phase extraction. In normal goats triclabendazole given orally was metabolized rapidly to its sulphoxide and sulphone derivatives. The maximum plasma concentrations for the sulphoxide and sulphone were similar ranging from 9 to 19 micrograms/ml and these were attained at an average 12.8 and 25.6 h, respectively, after administration. Both metabolites were eliminated slowly from plasma with elimination half-lives of 22.4 h for the sulphoxide and 19.4 h for the sulphone. They persisted at measurable concentrations in plasma for up to seven days. In milk, the two metabolites occurred in low concentrations and none of them was detectable (sulphoxide less than 0.04 microgram/ml, sulphone less than 0.02 microgram/ml) after seven days. The pharmacokinetic behaviour of triclabendazole was not altered in animals with fascioliasis. Efficacy of the drug against immature (six-week) F. hepatica was 100%.  相似文献   

17.
If the principal pharmacokinetic parameters of a veterinary drug-such as its elimination half-life from blood plasma, volume of distribution, plasma protein binding and metabolism-are known, then the presence and concentration of residues in animal tissue after administration of the drug can be predicted. This makes it possible to reduce the number of animals required by conventional residue testing and satisfies a legitimate demand of animal welfare groups. Using radioactively labelled drugs, the ratio of the parent substance to its metabolites can be established. Thus as a rule the determination of parent substance is sufficient for the routine determination of residues in foodstuffs. This is true in particular of sulfonamides. The pharmacokinetics of this class of substances are such that their main metabolites are eliminated from the animal's body faster than the parent substance. Other examples given are ceftriaxone, carprofen und climazolam.  相似文献   

18.
The aim of this study was to determine the pharmacokinetics of tramadol and its main metabolites after i.v. and i.m. injections. The pharmacokinetic cross-over study was carried out on 6 healthy male beagle dogs. Tramadol was administered by intravenous (i.v.) and intramuscular (i.m.) injection at 4 mg/kg. Tramadol and its main metabolites O-desmethyl-tramadol (M1), N-,N-didesmethyl-tramadol (M2) and N-,O-didesmethyl-tramadol (M5) concentrations were measured in plasma samples by a HPLC coupled with fluorimetric detection; pharmacokinetic evaluations were carried out with a compartmental and non-compartmental model for tramadol and its metabolites, respectively. The bioavailability of the drug, ranging between 84-102% (mean 92%), was within the generally accepted values for a positive bioequivalence decision of (80-125%). After the i.m. injection the mean plasma drug concentration peak was reached after a T(max) of 0.34 h with a C(max) of 2.52 microg/mL. No therapeutic relevant differences were observed between i.m. and i.v. administration. The minimal effective plasma concentration was reached after a few minutes and maintained for about 6-7 h in both administrations. M1 plasma concentration was low and the amounts of the other metabolites produced were analogous in both routes of administration. In conclusion, tramadol was rapidly and almost completely absorbed after i.m. administration and its systemic availability was equivalent to the i.v. injection. The different onset time and duration of action observed were very small and probably therapeutically irrelevant. The i.m. injection is a useful alternative to i.v. injection in the dog.  相似文献   

19.
An oral high dosage regimen of sulphadimethoxine (SDM) was examined in pigs. The dose (50 mg/kg) in the therapeutic range, showed nonlinear pharmacokinetics, and administered by drench once a day for 4 days. The unbound plasma concentration-time profile was compared with that of the dosage regimen based on nonlinear pharmacokinetics, where a pharmacokinetic model and parameters were used except for the first order absorption rate constant (ka) and bioavailability (F). F and ka were obtained from oral and intravenous administration of 20 and 10 mg/kg of SDM. The unbound plasma concentration was observed almost within the setting range by the dosage regimen through the experimental period. This result suggested that the dosage regimen, based on the nonlinear pharmacokinetic model, resulted in an appropriate effect in the clinical use.  相似文献   

20.
Summary

An oral high dosage regimen of sulphadimethoxine (SDM) was examined in pigs. The dose (50 mg/kg) in the therapeutic range, showed nonlinear pharmacokinetics, and administered by drench once a day for 4 days. The unbound plasma concentration‐time profile was compared with that of the dosage regimen based on nonlinear pharmacokinetics, where a pharmacokinetic model and parameters were used except for the first order absorption rate constant (ka) and bioavailability (F). F and ka were obtained from oral and intravenous administration of 20 and 10 mg/kg of SDM. The unbound plasma concentration was observed almost within the setting range by the dosage regimen through the experimental period. This result suggested that the dosage regimen, based on the nonlinear pharmacokinetic model, resulted in an appropriate effect in the clinical use.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号